ANXA1 and melanoma: This finding is in line with other studies in glioma [43]; breast cancer, lung cancer, and melanoma [30,44]; pancreatic cancer [45]; and gastric cancer [46], where an association between higher ANXA1 expression and lower survival has been described previously, all suggesting the involvement of ANXA1 in increased invasiveness and metastatic potential.